The excellent prognosis of mutated POLE/CRC seems to be better than mutated MMR/CRC, supporting that monitoring POLE mutation within clinical testing panels could improve risk stratification in somatic CRC. This evidence concerns the gene MRC1 and colorectal carcinoma.